Treatment Strategies for Canine Bph: Choosing the Right Approach

The management of benign prostatic hyperplasia (BPH) in dogs requires a tailored approach that considers the severity of clinical signs, the reproductive status of the animal, and the presence of concurrent conditions. Since BPH is primarily driven by androgenic stimulation, most treatment strategies aim to suppress or block androgen activity, thereby reducing prostate size and alleviating clinical signs¹. 

Castration: The Definitive Treatment 

Castration remains the most effective and widely recommended treatment for canine BPH. By eliminating the primary source of testosterone, it leads to a rapid decline in circulating androgen levels, resulting in significant prostatic regression. Studies have shown that prostate size can decrease by up to 70% following castration, with noticeable improvement in clinical signs occurring within weeks¹. 

Complete involution of the prostate typically occurs within 6–12 weeks after gonadectomy, although some studies report a substantial reduction in size within the first few weeks^1,2. The procedure induces apoptosis and atrophy of prostatic tissue, along with significant endocrine changes, including a marked decrease in testosterone levels¹. Despite its effectiveness, castration is not suitable for breeding dogs due to the irreversible loss of fertility. 

Medical Management in Breeding Dogs 

For dogs intended for breeding, medical therapy offers an alternative approach that preserves reproductive function while managing BPH. These therapies primarily target androgen production or action. 

Androgen receptor antagonists, such as osaterone acetate, act by inhibiting the uptake of dihydrotestosterone (DHT) within the prostate and blocking androgen receptor activity. This results in rapid regression of prostatic enlargement and improvement in clinical signs. Clinical studies have demonstrated that a significant proportion of dogs show improvement within the first week of treatment³. 

GnRH agonists, including deslorelin acetate, function by suppressing the hypothalamic-pituitary-gonadal axis, leading to reduced testosterone production. Although the onset of action may be slower compared to androgen receptor antagonists, these agents provide longer-lasting effects and reduced recurrence rates³. 

Progestins such as medroxyprogesterone acetate have also been used to reduce testosterone levels and induce prostatic shrinkage. However, their use is less common due to potential side effects and the availability of more targeted therapies¹. 

5α-Reductase Inhibitors: Targeting DHT Conversion 

5α-reductase inhibitors, such as finasteride, play a crucial role in the medical management of BPH by blocking the conversion of testosterone to DHT, the primary androgen responsible for prostatic growth⁴. This results in a reduction in prostate volume, vascularization, and associated clinical signs. 

Clinical studies have demonstrated that finasteride therapy leads to significant decreases in prostatic size and blood flow parameters over time, making it an effective option for long-term management. Additionally, finasteride has been shown to reduce levels of prostatic biomarkers such as CPSE and prostate-specific antigen without affecting hematological or biochemical parameters^1,5. 

PDE-5 Inhibitors: Emerging Therapeutic Option 

Phosphodiesterase-5 (PDE-5) inhibitors, particularly tadalafil, have been investigated for their role in managing BPH. By enhancing cyclic guanosine monophosphate (cGMP) activity, these drugs promote vasodilation and smooth muscle relaxation, which may contribute to reduced prostatic growth¹. 

Studies in dogs have shown that tadalafil administration leads to a decrease in prostatic size and serum DHT levels, along with improvements in ultrasonographic findings¹. Although promising, further research is needed to fully establish its role in routine veterinary practice. 

Combination and Advanced Therapies¹ 

Recent studies suggest that combination therapies, such as the use of deslorelin implants alongside androgen receptor antagonists, may provide enhanced and sustained reductions in prostate size. Additionally, newer approaches, including GnRH antagonists, have demonstrated rapid and effective reductions in prostatic volume, although their use is limited by cost and availability. 

Nonroutine therapies such as pulsed electromagnetic field therapy (PEMF) and vitamin D receptor agonists have also shown potential in reducing prostatic volume and improving tissue structure without affecting fertility or hormonal balance. 

Conclusion 

The management of canine BPH involves a range of therapeutic options, each with specific indications and limitations. While castration remains the most effective and definitive treatment, medical therapies provide valuable alternatives for breeding dogs and cases where surgery is not feasible. A thorough understanding of the mechanisms, efficacy, and clinical applications of these treatments allows veterinarians to develop individualized management plans that optimize outcomes and maintain quality of life. 

References: 

1. Derakhshandeh N, Mogheiseh A, Nazifi S. Diagnosis and Treatment of Benign Prostatic Hyperplasia in Dogs: New Approaches. Veterinary medicine international. 2025;2025(1):4153172. https://onlinelibrary.wiley.com/doi/pdf/10.1155/vmi/4153172 

2. H. Ruetten, M. Wehber, M. Murphy, et al., “A Retrospective Review of Canine Benign Prostatic Hyperplasia With and Without Prostatitis,” Clinical Teriogenology 13, no. 4 (2021): 360–366. https://pmc.ncbi.nlm.nih.gov/articles/PMC8782267/pdf/nihms-1768784.pdf 

3. W. Niza˙ nski, M. Ochota, C. Fontaine, and J. Pasikowska, “B- ´ Mode and Doppler Ultrasonographic Findings of Prostate Gland and Testes in Dogs Receiving Deslorelin Acetate or Osaterone Acetate,” Animals 10, no. 12 (2020): 2379. https://www.mdpi.com/2076-2615/10/12/2379 

4. O. A. Zitoun, A. M. Farhat, M. A. Mohamed, M. R. Hamad, B. Aramini, and K. H. Haider, “Management of Benign Prostate Hyperplasia (BPH) by Combinatorial Approach Using Alpha-1-Adrenergic Antagonists and 5-AlphaReductase Inhibitors,” European Journal of Pharmacology 883 (2020): 173301. https://www.academia.edu/download/99575367/European_20Journal_20of_20Pharmacology_202020.pdf 

5. D. S. Angrimani, M. C. P. Francischini, M. M. Brito, and C. I. Vannucchi, “Prostatic Hyperplasia: Vascularization, Hemodynamic and Hormonal Analysis of Dogs Treated with Finasteride or Orchiectomy,” PLoS One 15, no. 6 (2020): e0234714. https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0234714&type=printable